

Debra H Josephs

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5081914/publications.pdf>

Version: 2024-02-01

61
papers

2,422
citations

236925

25
h-index

214800

47
g-index

62
all docs

62
docs citations

62
times ranked

4486
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting folate receptor alpha for cancer treatment. <i>Oncotarget</i> , 2016, 7, 52553-52574.	1.8	308
2	IgG4 subclass antibodies impair antitumor immunity in melanoma. <i>Journal of Clinical Investigation</i> , 2013, 123, 1457-1474.	8.2	181
3	Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma. <i>Frontiers in Immunology</i> , 2019, 10, 453.	4.8	177
4	Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs). <i>Oncolmmunology</i> , 2018, 7, e1395127.	4.6	117
5	Regional Activation of Myosin II in Cancer Cells Drives Tumor Progression via a Secretory Cross-Talk with the Immune Microenvironment. <i>Cell</i> , 2019, 176, 757-774.e23.	28.9	117
6	A tool kit for rapid cloning and expression of recombinant antibodies. <i>Scientific Reports</i> , 2014, 4, 5885.	3.3	85
7	Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors. <i>Therapeutic Drug Monitoring</i> , 2013, 35, 562-587.	2.0	77
8	BRAF inhibitors: resistance and the promise of combination treatments for melanoma. <i>Oncotarget</i> , 2017, 8, 78174-78192.	1.8	75
9	Effects of <i>BRAF</i> Mutations and <i>BRAF</i> Inhibition on Immune Responses to Melanoma. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2769-2783.	4.1	73
10	Combined anti- <i>PD-1</i> and anti- <i>CTLA-4</i> checkpoint blockade: Treatment of melanoma and immune mechanisms of action. <i>European Journal of Immunology</i> , 2021, 51, 544-556.	2.9	71
11	Anti-Folate Receptor Alpha-Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 5098-5111.	7.0	65
12	Anti-Folate Receptor- α IgE but not IgG Recruits Macrophages to Attack Tumors via TNF α /MCP-1 Signaling. <i>Cancer Research</i> , 2017, 77, 1127-1141.	0.9	58
13	Elevated IgG4 in patient circulation is associated with the risk of disease progression in melanoma. <i>Oncolmmunology</i> , 2015, 4, e1032492.	4.6	53
14	IgG subclass switching and clonal expansion in cutaneous melanoma and normal skin. <i>Scientific Reports</i> , 2016, 6, 29736.	3.3	52
15	Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis. <i>BJU International</i> , 2011, 108, 1279-1283.	2.5	50
16	IgE re-programs alternatively-activated human macrophages towards pro-inflammatory anti-tumoural states. <i>EBioMedicine</i> , 2019, 43, 67-81.	6.1	49
17	Factors Affecting COVID-19 Outcomes in Cancer Patients: A First Report From Guy's Cancer Center in London. <i>Frontiers in Oncology</i> , 2020, 10, 1279.	2.8	49
18	IgE immunotherapy. <i>MAbs</i> , 2014, 6, 54-72.	5.2	46

#	ARTICLE	IF	CITATIONS
19	Therapeutic IgE Antibodies: Harnessing a Macrophage-Mediated Immune Surveillance Mechanism against Cancer. <i>Cancer Research</i> , 2017, 77, 2779-2783.	0.9	42
20	Risk of COVID-19 death in cancer patients: an analysis from Guyâ€™s Cancer Centre and Kingâ€™s College Hospital in London. <i>British Journal of Cancer</i> , 2021, 125, 939-947.	6.4	41
21	Tumour-associated macrophage polarisation and re-education with immunotherapy. <i>Frontiers in Bioscience - Elite</i> , 2015, 7, 334-351.	1.8	41
22	AllergoOncology: ultra-low IgE, a potential novel biomarker in cancerâ€™a Position Paper of the European Academy of Allergy and Clinical Immunology (EAACI). <i>Clinical and Translational Allergy</i> , 2020, 10, 32.	3.2	40
23	Beta-glucan contamination of pharmaceutical products: How much should we accept?. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 1289-1301.	4.2	39
24	Molecular imaging in clinical trials. <i>Targeted Oncology</i> , 2009, 4, 151-168.	3.6	38
25	Chronic inflammation markers are associated with risk of pancreatic cancer in the Swedish AMORIS cohort study. <i>BMC Cancer</i> , 2019, 19, 858.	2.6	30
26	Consensus in Bladder Cancer Research Priorities Between Patients and Healthcare Professionals Using a Four-stage Modified Delphi Method. <i>European Urology</i> , 2019, 76, 258-259.	1.9	30
27	Association Between Vitamin D and Novel SARS-CoV-2 Respiratory Dysfunction â€™ A Scoping Review of Current Evidence and Its Implication for COVID-19 Pandemic. <i>Frontiers in Physiology</i> , 2020, 11, 564387.	2.8	27
28	Basophils from Cancer Patients Respond to Immune Stimuli and Predict Clinical Outcome. <i>Cells</i> , 2020, 9, 1631.	4.1	26
29	Pharmacodynamic Biomarker Development for PI3K Pathway Therapeutics. <i>Translational Oncogenomics</i> , 2016, Suppl. 1, 33-49.	1.7	25
30	Immune mediator expression signatures are associated with improved outcome in ovarian carcinoma. <i>Oncot Immunology</i> , 2019, 8, e1593811.	4.6	20
31	Functionally Active Fc Mutant Antibodies Recognizing Cancer Antigens Generated Rapidly at High Yields. <i>Frontiers in Immunology</i> , 2017, 8, 1112.	4.8	17
32	AllergoOncology: Microbiota in allergy and cancerâ€™A European Academy for Allergy and Clinical Immunology position paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1037-1051.	5.7	17
33	IgE Antibodies against Cancer: Efficacy and Safety. <i>Antibodies</i> , 2020, 9, 55.	2.5	17
34	Harnessing Therapeutic IgE Antibodies to Re-educate Macrophages against Cancer. <i>Trends in Molecular Medicine</i> , 2020, 26, 615-626.	6.7	17
35	Therapeutic targets and new directions for antibodies developed for ovarian cancer. <i>MAbs</i> , 2016, 8, 1437-1455.	5.2	15
36	IgE Activates Monocytes from Cancer Patients to Acquire a Pro-Inflammatory Phenotype. <i>Cancers</i> , 2020, 12, 3376.	3.7	15

#	ARTICLE	IF	CITATIONS
37	Insights from IgE Immune Surveillance in Allergy and Cancer for Anti-Tumour IgE Treatments. <i>Cancers</i> , 2021, 13, 4460.	3.7	15
38	Development of downstream processing to minimize beta- β -glucan impurities in GMP-manufactured therapeutic antibodies. <i>Biotechnology Progress</i> , 2016, 32, 1494-1502.	2.6	14
39	AllergoOncology: Expression platform development and functional profiling of an anti-HER2 IgE antibody. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1985-1989.	5.7	14
40	Basophil activation test in cancer patient blood evaluating potential hypersensitivity to an anti-tumor IgE therapeutic candidate. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2069-2073.	5.7	14
41	Clinical and Translational Significance of Basophils in Patients with Cancer. <i>Cells</i> , 2022, 11, 438.	4.1	14
42	Association of Serum Immunoglobulin Levels with Solid Cancer: A Systematic Review and Meta-analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 527-538.	2.5	13
43	COVID-19 Risk Factors for Cancer Patients: A First Report with Comparator Data from COVID-19 Negative Cancer Patients. <i>Cancers</i> , 2021, 13, 2479.	3.7	13
44	Abstract CT141: Phase 1 trial of MOv18, a first-in-class IgE antibody therapy for cancer. <i>Cancer Research</i> , 2020, 80, CT141-CT141.	0.9	13
45	Comparative reactivity of human IgE to cynomolgus monkey and human effector cells and effects on IgE effector cell potency. <i>MAbs</i> , 2014, 6, 509-522.	5.2	12
46	<i>In vivo</i> safety profile of a CSPG4-directed IgE antibody in an immunocompetent rat model. <i>MAbs</i> , 2020, 12, 1685349.	5.2	11
47	Patient-reported outcomes in randomised clinical trials of bladder cancer: an updated systematic review. <i>BMC Urology</i> , 2019, 19, 86.	1.4	10
48	Immunotherapy using IgE or CAR T cells for cancers expressing the tumor antigen SLC3A2. , 2021, 9, e002140.		10
49	Potential for monocyte recruitment by IgE immunotherapy for cancer in a rat model of tumour metastasis. <i>Lancet, The</i> , 2015, 385, S53.	13.7	9
50	Chronic inflammatory diseases, anti-inflammatory medications and risk of prostate cancer: a population-based case-control study. <i>BMC Cancer</i> , 2019, 19, 612.	2.6	9
51	Neoadjuvant chemotherapy for muscle invasive bladder cancer: a nationwide investigation on survival. <i>Scandinavian Journal of Urology</i> , 2019, 53, 206-212.	1.0	8
52	Graham Roberts Study protocol: first β -trials within cohort study β ™ for bladder cancer. <i>BMJ Open</i> , 2019, 9, e029468.	1.9	7
53	Serum Immunoglobulin G Is Associated With Decreased Risk of Pancreatic Cancer in the Swedish AMORIS Study. <i>Frontiers in Oncology</i> , 2020, 10, 263.	2.8	7
54	Association between serum markers of the humoral immune system and inflammation in the Swedish AMORIS study. <i>BMC Immunology</i> , 2021, 22, 61.	2.2	7

#	ARTICLE	IF	CITATIONS
55	Macrophages in ovarian cancer and their interactions with monoclonal antibody therapies. <i>Clinical and Experimental Immunology</i> , 2022, 209, 4-21.	2.6	7
56	AllergoOncology: Danger signals in allergology and oncology: AÂEuropean Academy of Allergy and Clinical Immunology (EAACI) Position Paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2594-2617.	5.7	5
57	Immunoglobulin E and Allergy: Antibodies in Immune Inflammation and Treatment. <i>Microbiology Spectrum</i> , 2013, 1, .	3.0	4
58	Serum immunoglobulin levels and the risk of bladder cancer in the AMORIS Cohort. <i>Cancer Epidemiology</i> , 2019, 62, 101584.	1.9	4
59	<i>In vivo</i> trafficking of a tumor-targeting IgE antibody: molecular imaging demonstrates rapid hepatobiliary clearance compared to IgG counterpart. <i>Oncolmmunology</i> , 2021, 10, 1966970.	4.6	2
60	Abstract S12-03: Clinical and demographic characteristics associated with shorter time to COVID-19 death. , 2021, , .		0
61	Immunoglobulin E and Allergy: Antibodies in Immune Inflammation and Treatment. , 0, , 75-102.		0